Dr Greg Brooke

School of Biological Sciences
Dr Greg Brooke



Jul 2000 Research Associate, Department of Cancer Biology, Imperial College London Oct 2001 PhD, Department of Cancer Biology, Imperial College London Oct 2005 Post-Doctoral Research Fellow, Department of Surgery and Cancer, Imperial College London Oct 2010 Senior Research Fellow, Martin Harris Fellowship, Department of Surgery and Cancer, Imperial College London Jul 2013 Lecturer, School of Biological Sciences, University of Essex Self-funded students, or candidates interested in applying for fellowships to undertake research in my laboratory, are welcome to contact me ( at any time. Group Members PhD Students: Miss Rosie Bryan Mr Mohammad Alkheilewi Mrs Amna Allafi(co-supervisor) Research Associates: Miss Angela Pine MD Students (Clinical Fellow): Gurvir Josan (co-supervisor) External Research Collaborations Professor Charlotte Bevan (Imperial College London) Professor Simak Ali (Imperial College London) Dr Jody Mason (University of Bath)


  • BSc Biology (1st Class Hons) Queen Mary London, (2000)

  • PhD (Androgen Receptor Variants in Prostate Cancer Progression) Imperial College London, (2005)


University of Essex

  • Lecturer in Molecular and Cellular Biology, University of Essex (1/7/2013 - present)

Other academic

  • Research Associate, Imperial College London (3/7/2000 - 1/10/2001)

  • Post-Doctoral Research Fellow, Imperial College London (3/10/2005 - 30/9/2010)

  • Senior Research Fellow (Martin Harris Fellowship), Imperial College London (1/10/2010 - 30/6/2013)

Research and professional activities

Research interests

Identify and characterise factors that promote tumour growth and therapy resistance in prostate and breast cancer.

Open to supervise

Prostate Cancer

Characterisation of mechanisms of therapy resistance Identification of novel therapeutic targets The development of novel therapies for the treatment of prostate cancer

Key words: Androgen Receptor
Open to supervise

Breast Cancer

Characterisation of the role of androgen receptor signalling in breast cancer development and therapy resistance

Key words: Therapy Resistance
Open to supervise

Development of genetic probes based on GFP for non-invasive detection and quantification of reactive oxygen species and antioxidants in subcellular compartments

Fluorescent protein biosensors are showing great promise in allowing the real time, spatial and quantitative detection of specific small molecules in living cells. We have engineered and used these biosensors in cells of the leaf to detect hydrogen peroxide, glutathione, lipid peroxides, oxidised ascorbate (vitamin C) and changes in pH. The detection spatially in real time has allowed us to develop a new hypothesis on the spatial dependency of signalling from chloroplasts to the nucleus in leaves exposed to high light - only those chloroplast in contact with the nucleus are capable of triggering a change in gene expression in response to high light. We have provided evidence, using these biosensors, that hydrogen peroxide is the mobile signal that transfers directly to the nucleus from connected chloroplasts. This work has led to further developments in biosensor technology in my laboratory, which in collaboration with colleagues in the School is beginning to extend our detection capability to animals cells and for studying other important signalling molecules.

Key words: green fluorescent protein

Current research

The role of 90kDa Ribosomal S6 Kinases in Steroid signalling

Conferences and presentations

2014 Androgen Receptor Signalling in Breast Cancer. Essex County Hospital, Colchester


2014 Targetting Androgen Receptor Signalling in Prostate Cancer. Eastern Arc Cancer Conference, Colchester


2014 Targetting Androgen Receptor Signalling in Advanced Prostate Cancer. Essex Biomedical Sciences Institute Conference, Colchester


2012 Inhibition of androgen signalling by AR corepressors in prostate cancer. European Association for Urology, Strasbourg, France?


2010 FUS/TLS is a key modulator of androgen receptor signalling and prostate cancer growth. Androgens 2010, Leuven, Belgium


?2010 Whats all the FUS about? Young Prostate Researchers Conference, Cambridge


?2010 The Role of FUS in Prostate Cancer Progression National Cancer Research Institute (NCRI), Liverpool?


2010 The Design of Novel Therapeutic Strategies to Inhibit Prostate Cancer Progression. Prostate Cancer Research Foundation (PCRF) Forum, York?


2010 The Role of FUS in Prostate Cancer Progression. National Prostate Conference, London


?2010 FUS/TLS is a key modulator of androgen receptor signalling and prostate cancer growth. Northern Institute of Cancer Research, University of Newcastle


?2008 Androgen Signalling in Advanced Prostate Cancer. University of Portsmouth


Teaching and supervision

Current teaching responsibilities

  • Quantitative methods for Life Sciences (BS141)

  • Enterprise and Employability for the Biosciences (BS211)

  • Biomedical Science: Practice and Employability (BS214)

  • Cell Biology (BS225)

  • Cell Biology and Cellular Pathology (BS238)

  • Cell Signalling (BS327)

  • Molecular Basis of Cancer (BS349)

  • Research Project in Biomolecular Science (BS831)

  • Research Project in Ecological and Marine Sciences (BS832)

Previous supervision

Ryan Cronin
Ryan Cronin
Thesis title: The Role of P90 Ribosomal S6 Kinases (Rsks) in Steroid Receptor Signalling
Degree subject: Biochemistry
Degree type: Master of Science (by Dissertation)
Awarded date: 28/6/2019
Eleanor Elisabeth Louise Rees
Eleanor Elisabeth Louise Rees
Thesis title: Characterisation of Androgen Receptor Signalling and Metabolism in Prostate Cancer
Degree subject: Cell and Molecular Biology
Degree type: Master of Science (by Dissertation)
Awarded date: 17/4/2019
Amna Emhemed Allafi
Amna Emhemed Allafi
Thesis title: The Development of a Novel Therapeutic Strategy for the Treatment of Prostate Cancer By Targeting Metabolic Signalling
Degree subject: Molecular Medicine
Degree type: Doctor of Philosophy
Awarded date: 5/11/2018
Rosie Alexandra Bryan
Rosie Alexandra Bryan
Thesis title: The Role of Androgen Receptor Signalling in Endocrine Resistant Breast Cancer
Degree subject: Cell and Molecular Biology
Degree type: Doctor of Philosophy
Awarded date: 3/7/2018
Angela Christine Pine
Angela Christine Pine
Thesis title: Novel Techniques to Target Androgen Signalling in Prostate Cancer
Degree subject: Cell and Molecular Biology
Degree type: Master of Science (by Dissertation)
Awarded date: 20/2/2017


Journal articles (20)

Mohr, A., Chu, T., Brooke, GN. and Zwacka, RM., (2019). MSC.sTRAIL Has Better Efficacy than MSC.FL-TRAIL and in Combination with AKTi Blocks Pro-Metastatic Cytokine Production in Prostate Cancer Cells. Cancers. 11 (4), 568-568

Pine, AC., Fioretti, FF., Brooke, GN. and Bevan, CL., (2016). Advances in genetics: widening our understanding of prostate cancer. F1000Research. 5, 1512-1512

Brooke, GN., Gamble, SC., Hough, MA., Begum, S., Dart, DA., Odontiadis, M., Powell, SM., Fioretti, FM., Bryan, RA., Waxman, J., Wait, R. and Bevan, CL., (2015). Antiandrogens Act as Selective Androgen Receptor Modulators at the Proteome Level in Prostate Cancer Cells. Molecular & Cellular Proteomics. 14 (5), 1201-1216

Querol Cano, L., Lavery, DN., Sin, S., Spanjaard, E., Brooke, GN., Tilman, JD., Abroaf, A., Gaughan, L., Robson, CN., Heer, R., Mauri, F., de Rooij, J., Driouch, K. and Bevan, CL., (2015). The co-chaperone p23 promotes prostate cancer motility and metastasis. Molecular Oncology. 9 (1), 295-308

Fioretti, FM., Sita-Lumsden, A., Bevan, CL. and Brooke, GN., (2014). Revising the role of the androgen receptor in breast cancer. Journal of Molecular Endocrinology. 52 (3), R257-R265

Brooke, GN., Powell, SM., Lavery, DN., Waxman, J., Buluwela, L., Ali, S. and Bevan, CL., (2014). Engineered repressors are potent inhibitors of androgen receptor activity. Oncotarget. 5 (4), 959-969

Rudraraju, B., Droog, M., Abdel-Fatah, TMA., Zwart, W., Giannoudis, A., Malki, MI., Moore, D., Patel, H., Shaw, J., Ellis, IO., Chan, S., Brooke, GN., Nevedomskaya, E., Nigro, CL., Carroll, J., Coombes, RC., Bevan, C., Ali, S. and Palmieri, C., (2014). Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. Breast Cancer Research and Treatment. 147 (2), 295-309

Ottaviani, S., Brooke, GN., O'Hanlon-Brown, C., Waxman, J., Ali, S. and Buluwela, L., (2013). Characterisation of the androgen regulation of glycine N-methyltransferase in prostate cancer cells. Journal of Molecular Endocrinology. 51 (3), 301-312

Sita-Lumsden, A., Fletcher, CE., Dart, DA., Brooke, GN., Waxman, J. and Bevan, CL., (2013). Circulating nucleic acids as biomarkers of prostate cancer. Biomarkers in Medicine. 7 (6), 867-877

Dart, DA., Brooke, GN., Sita-Lumsden, A., Waxman, J. and Bevan, CL., (2012). Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens. Oncogene. 31 (43), 4588-4598

Reebye, V., Querol Cano, L., Lavery, DN., Brooke, GN., Powell, SM., Chotai, D., Walker, MM., Whitaker, HC., Wait, R., Hurst, HC. and Bevan, CL., (2012). Role of the HSP90-Associated Cochaperone p23 in Enhancing Activity of the Androgen Receptor and Significance for Prostate Cancer. Molecular Endocrinology. 26 (10), 1694-1706

Grosdidier, S., Carbó, LR., Buzón, V., Brooke, G., Nguyen, P., Baxter, JD., Bevan, C., Webb, P., Estébanez-Perpiñá, E. and Fernández-Recio, J., (2012). Allosteric Conversation in the Androgen Receptor Ligand-Binding Domain Surfaces. Molecular Endocrinology. 26 (7), 1078-1090

Brooke, GN., Culley, RL., Dart, DA., Mann, DJ., Gaughan, L., McCracken, SR., Robson, CN., Spencer-Dene, B., Gamble, SC., Powell, SM., Wait, R., Waxman, J., Walker, MM. and Bevan, CL., (2011). FUS/TLS Is a Novel Mediator of Androgen-Dependent Cell-Cycle Progression and Prostate Cancer Growth. Cancer Research. 71 (3), 914-924

Brooke, G. and Bevan, C., (2009). The Role of Androgen Receptor Mutations in Prostate Cancer Progression. Current Genomics. 10 (1), 18-25

Brooke, GN., Parker, MG. and Bevan, CL., (2008). Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene. 27 (21), 2941-2950

Gamble, SC., Chotai, D., Odontiadis, M., Dart, DA., Brooke, GN., Powell, SM., Reebye, V., Varela-Carver, A., Kawano, Y., Waxman, J. and Bevan, CL., (2007). Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene. 26 (12), 1757-1768

Powell, SM., Brooke, GN., Whitaker, HC., Reebye, V., Gamble, SC., Chotai, D., Dart, DA., Belandia, B. and Bevan, CL., (2006). Mechanisms of androgen receptor repression in prostate cancer. Biochemical Society Transactions. 34 (6), 1124-1127

Vigushin, DM., Mirsaidi, N., Brooke, G., Sun, C., Pace, P., Inman, L., Moody, CJ. and Coombes, RC., (2004). Gliotoxin Is a Dual Inhibitor of Farnesyltransferase and Geranylgeranyltransferase I with Antitumor Activity Against Breast Cancer In Vivo. Medical Oncology. 21 (1), 21-30

Vigushin, DM., Brooke, G., Willows, D., Coombes, RC. and Moody, CJ., (2003). Pyrazino[1,2- a ]indole-1,4-diones, simple analogues of gliotoxin, as selective inhibitors of geranylgeranyltransferase I. Bioorganic & Medicinal Chemistry Letters. 13 (21), 3661-3663

Marson, CM., Rioja, AS., Brooke, G., Coombes, RC. and Vigushin, DM., (2002). Cyclic acid anhydrides as a new class of potent, selective and non-peptidic inhibitors of geranylgeranyl transferase. Bioorganic & Medicinal Chemistry Letters. 12 (2), 255-259

Grants and funding


Bioimaging of dehydroascorbate and (phospho)lipid hydroperoxides: The development of fluorescent protein biosensors

Biotechnology & Biology Science Res.Council

The development of DNAzymes for the treatment of prostate cancer, and a program to design and predict DNAzyme efficiency

Rosetrees Trust


MSC - Mediated delivery of TRAIL for the treatment of prostate cancer.

Prostate Cancer UK


Engineered androgen receptor repressors for prostate cancer therapy

Janssen Biotech Inc

Characterisation of non-genomic androgen signalling in prostate cancer

Wellcome Trust


Identification and validation of new biomarkers and drug targets for prostate cancer: The continuing investigation

Colchester Hospitals NHS Foundation Trust

+44 (0) 1206 873332


3SW.5.07, Colchester Campus